Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...

Recursion outlines extended cash runway into early 2028 as platform efficiency accelerates

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...

Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ...
Visual Studio Magazine

Decision Tree Regression from Scratch Without Pointers or Recursion Using C#

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...
Yahoo Finance

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...
i-scoop.eu

Recursive self improvement, AI that makes itself better

Imagine a computer program that doesn’t just do what it’s told, but actively looks at its own code, identifies weaknesses, and rewrites itself to be smarter. Then, with its newly increased ...
Forbes

What’s Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Benzinga.com

Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Hosted on MSN

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...